You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Salivary DNA methylation panel to diagnose HPV-positive and HPV-negative head and neck cancers
|
|---|---|
| Published in |
BMC Cancer, September 2016
|
| DOI | 10.1186/s12885-016-2785-0 |
| Pubmed ID | |
| Authors |
Yenkai Lim, Yunxia Wan, Dimitrios Vagenas, Dmitry A. Ovchinnikov, Chris F. L. Perry, Melissa J. Davis, Chamindie Punyadeera |
| Abstract |
Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous group of tumours with a typical 5 year survival rate of <40 %. DNA methylation in tumour-suppressor genes often occurs at an early stage of tumorigenesis, hence DNA methylation can be used as an early tumour biomarker. Saliva is an ideal diagnostic medium to detect early HNSCC tumour activities due to its proximity to tumour site, non-invasiveness and ease of sampling. We test the hypothesis that the surveillance of DNA methylation in five tumour-suppressor genes (RASSF1α, p16 (INK4a) , TIMP3, PCQAP/MED15) will allow us to diagnose HNSCC patients from a normal healthy control group as well as to discriminate between Human Papillomavirus (HPV)-positive and HPV-negative patients. Methylation-specific PCR (MSP) was used to determine the methylation levels of RASSF1α, p16 (INK4a) , TIMP3 and PCQAP/MED15 in DNA isolated from saliva. Statistical analysis was carried out using non-parametric Mann-Whitney's U-test for individually methylated genes. A logistic regression analysis was carried out to determine the assay sensitivity when combing the five genes. Further, a five-fold cross-validation with a bootstrap procedure was carried out to determine how well the panel will perform in a real clinical scenario. Salivary DNA methylation levels were not affected by age. Salivary DNA methylation levels for RASSF1α, p16 (INK4a) , TIMP3 and PCQAP/MED15 were higher in HPV-negative HNSCC patients (n = 88) compared with a normal healthy control group (n = 122) (sensitivity of 71 % and specificity of 80 %). Conversely, DNA methylation levels for these genes were lower in HPV-positive HNSCC patients (n = 45) compared with a normal healthy control group (sensitivity of 80 % and specificity of 74 %), consistent with the proposed aetiology of HPV-positive HNSCCs. Salivary DNA tumour-suppressor methylation gene panel has the potential to detect early-stage tumours in HPV-negative HNSCC patients. HPV infection was found to deregulate the methylation levels in HPV-positive HNSCC patients. Large-scale double-blinded clinical trials are crucial before this panel can potentially be integrated into a clinical setting. |
X Demographics
The data shown below were collected from the profiles of 15 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 33% |
| Greece | 1 | 7% |
| Spain | 1 | 7% |
| Unknown | 8 | 53% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 67% |
| Scientists | 5 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Sweden | 1 | 1% |
| France | 1 | 1% |
| Unknown | 72 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 19% |
| Student > Bachelor | 13 | 18% |
| Student > Ph. D. Student | 13 | 18% |
| Student > Master | 7 | 9% |
| Student > Postgraduate | 4 | 5% |
| Other | 9 | 12% |
| Unknown | 14 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 31 | 42% |
| Biochemistry, Genetics and Molecular Biology | 13 | 18% |
| Agricultural and Biological Sciences | 12 | 16% |
| Social Sciences | 1 | 1% |
| Nursing and Health Professions | 1 | 1% |
| Other | 2 | 3% |
| Unknown | 14 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 September 2016.
All research outputs
#4,078,205
of 22,889,074 outputs
Outputs from BMC Cancer
#973
of 8,326 outputs
Outputs of similar age
#68,256
of 321,669 outputs
Outputs of similar age from BMC Cancer
#21
of 168 outputs
Altmetric has tracked 22,889,074 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,326 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 321,669 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 168 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.